Abstract | OBJECTIVE: To investigate the effect and molecular mechanisms of different doses of 8-hydroxy dihydroberberine (Hdber) for the treatment of hyperlipidemia in rats. METHODS: A rat model of hyperlipidemia was established by feeding rats a high-fat diet for 4 weeks in 70 rats of 80 animals, and 10 rats were randomly selected as control group. The hyperlipidemic rats were then randomly divided into the following groups: a model group (MOD); a berberine group [BBR, 156 mg/(kg day)]; Hdber groups, which were treated with different doses of Hdber [78, 39 and 19.5 mg/(kg day)]; and a simvastatin group [SIM, 4 mg/(kg day)]. The corresponding therapy was administered to the rats of each treatment via gastric tubes. Normal animals were used as a control group. The blood levels of various lipids, including total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, free fatty acid (FFA), apolipoprotein AI( Apo-AI) and apolipoprotein B ( Apo-B) were examined. The protein expressions of low-density lipoprotein receptor ( LDL-R), sterol regulatory element-binding protein 2 (SREBP-2), 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and proprotein convertase subtilisin/kexin type 9 (PCSK-9) in liver tissues were determined by Western blot analysis. RESULTS: Compared with the control group of rats, the model group demonstrated a deteriorated blood lipid profile and exhibited increased expression levels of PCSK-9 protein in their liver tissues (P<0.01). In addition, the high-fat diet decreased the expression levels of LDL-R, SREBP-2 and HMGCR proteins in murine liver tissues. However, the addition of berberine or Hdber reversed the blood lipid profile changes (P<0.05 or P<0.01), decreased the expression levels of PCSK-9 proteins (P<0.01), and increased the expression levels of LDL-R proteins in the hyperlipidemic rats (P<0.01). These compounds did not significantly influence the expression levels of SREBP-2 and HMGCR proteins in the hyperlipidemic rats. CONCLUSIONS: Hdber is effective in the treatment of hyperlipidemia in rats. The therapeutic mechanisms of Hdber may be associated with increasing the expression of LDL-R protein and decreasing the expression of PCSK-9 protein in liver tissues.
|
Authors | De-liang Liu, Li-jun Xu, Hui Dong, Guang Chen, Zhao-yi Huang, Xin Zou, Kai-fu Wang, Yun-huan Luo, Fu-er Lu |
Journal | Chinese journal of integrative medicine
(Chin J Integr Med)
Vol. 21
Issue 2
Pg. 132-8
(Feb 2015)
ISSN: 1672-0415 [Print] China |
PMID | 24893659
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Apolipoprotein A-I
- Apolipoproteins B
- Lipids
- Receptors, LDL
- Sterol Regulatory Element Binding Protein 2
- Berberine
- dihydroberberine
- Hydroxymethylglutaryl CoA Reductases
- PCSK9 protein, rat
- Proprotein Convertase 9
- Serine Endopeptidases
|
Topics |
- Animals
- Apolipoprotein A-I
(blood)
- Apolipoproteins B
(blood)
- Berberine
(analogs & derivatives, pharmacology, therapeutic use)
- Hydroxymethylglutaryl CoA Reductases
(metabolism)
- Hyperlipidemias
(blood, drug therapy)
- Lipids
(blood)
- Liver
(drug effects, metabolism)
- Male
- Proprotein Convertase 9
- Rats, Wistar
- Receptors, LDL
(metabolism)
- Serine Endopeptidases
(metabolism)
- Sterol Regulatory Element Binding Protein 2
(metabolism)
|